First Line Metastatic Colorectal Cancer Therapy in Combination with FOLFOX - HORIZON III

Study identifier:D8480C00013

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination with 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination with FOLFOX in Patients with Previously Untreated Metastatic Colorectal Cancer

Medical condition

Colorectal Cancer

Phase

Phase 2/3

Healthy volunteers

No

Study drug

Cediranib, Bevacizumab, 5-fluorouracil ( in FOLFOX), Leucovorin (in FOLFOX), Oxaliplatin (in FOLFOX)

Sex

All

Actual Enrollment

1814

Study type

Interventional

Age

18 Years - 149 Years

Date

Study Start Date: 01 Aug 2006
Primary Completion Date: 01 Nov 2009
Estimated Study Completion Date: 01 Dec 2015

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Jun 2015 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria